Novel approach to cancer therapeutics using comparative cancer biology

TL;DR: It is suggested that Ran is required for and is a potential therapeutic target of Myc-driven cancer progression in both breast and lung cancers.

TL;DR: There is a white circle in Figure 6 that was erroneously introduced into a panel on the left side and the following link provides the correct version of Figure 6.

TL;DR: In this paper, a balance between stimulatory and inhibitory signals regulates the immune response to cancer, which contributes to immune resistance, especially against tumor antigen-specific T-cells.

TL;DR: ALDOA could contribute to the progress of cancer, at least partially through its association with genes relevant to cell cycle independent of glycolysis, as well as with CDC45 and CCNB2 in breast tumors.

TL;DR: Combined ganetespib/erlotinib exposure stabilized EGFR protein levels in an inactive state and completely abrogated extracellular-signal-regulated kinase (ERK) and AKT signaling activity, indicating a potentially important complementary strategy to targeted TKI inhibition alone for inducing substantial antitumor responses and overcoming resistance.

TL;DR: A role for discrete motifs in the enhancer domain of IRF-1 in directing polyubiquitination and degradation is established and support is given to the idea that the degradation of selective substrates can be regulated at multiple steps in the ubiquitin-proteasome system.

TL;DR: Immunohistochemical staining of archival tissue identified IRF-1 and -2 in human melanomas; this had not been previously demonstrated and may account for the less aggressive biologic features of IRf-1-expressing melanomas.